---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040002"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T06:33:54.653405+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Catalyst Biosciences receives Nasdaq delisting notice for minimum bid price non-compliance

## Summary
- Received Nasdaq notice on Nov 2, 2022; stock closed below $1.00 for 30 consecutive trading days.
- Company has 180 calendar days, until May 1, 2023, to regain compliance with Minimum Bid Price Requirement.
- If bid price closes at or above $1.00 for 10 consecutive days before deadline, compliance achieved.
- If not cured, Nasdaq may grant a second 180-day grace period if Company meets other listing standards.
- Failure to cure could lead to delisting; Company may appeal to a Nasdaq hearings panel.

## SEC filing metadata
- accession: 0001140361-22-040002
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036122040002/0001140361-22-040002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036122040002/brhc10043734_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040002
- JSON: https://secwatch.observer/filing/0001140361-22-040002.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040002.txt

## Key facts
- Listing & Compliance Notices
  GYRE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: November 2, 2022, Catalyst Biosciences, Inc., a Delaware Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Marke
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000114036122040002/0001140361-22-040002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.